A Golimumab Phase 3b, Multicenter, Assessment of Intravenous Efficacy in Rheumatoid Arthritis Subjects Who Have Diminished Disease Control Despite Treatment With Infliximab (REMICADE®)
Clinical trial NCT01962974 · TERMINATED
Trial details
- NCT number
- NCT01962974
- Sponsor
- Janssen Biotech, Inc.
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2013-10-01
- Primary completion
- 2014-12-01
- Enrollment
- 7
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.